Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

(2015) Stefan Zeuzem et al.   ANNALS OF INTERNAL MEDICINE

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

(2015) Xavier Forns et al.   JOURNAL OF HEPATOLOGY

Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study

(2014) Fred Poordad et al.   CLINICAL INFECTIOUS DISEASES

Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus

(2014) Eric M. Yoshida et al.   HEPATOLOGY

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

(2013) James C. Sullivan et al.   CLINICAL INFECTIOUS DISEASES

Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies

(2013) Jianmeng Chen et al.   GASTROENTEROLOGY

Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection

(2013) N. Akuta et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies

(2013) Richard J.O. Barnard et al.   VIROLOGY

Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents

(2012) Heiner Wedemeyer et al.   HEPATOLOGY

Clinical relevance of HCV antiviral drug resistance

(2012) C Welsch et al.   Current Opinion in Virology